Calcium channel blocker use and risk of Parkinson's disease.
Identifieur interne : 001701 ( PubMed/Corpus ); précédent : 001700; suivant : 001702Calcium channel blocker use and risk of Parkinson's disease.
Auteurs : Kelly Claire Simon ; Xiang Gao ; Honglei Chen ; Michael A. Schwarzschild ; Alberto AscherioSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Calcium Channel Blockers.
- drug therapy : Hypertension.
- etiology : Parkinson Disease.
- Female, Humans, Male, Nurses, Proportional Hazards Models, Risk.
Abstract
We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.
DOI: 10.1002/mds.23191
PubMed: 20669249
Links to Exploration step
pubmed:20669249Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Calcium channel blocker use and risk of Parkinson's disease.</title>
<author><name sortKey="Simon, Kelly Claire" sort="Simon, Kelly Claire" uniqKey="Simon K" first="Kelly Claire" last="Simon">Kelly Claire Simon</name>
<affiliation><nlm:affiliation>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ksimon@hsph.harvard.edu</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name>
</author>
<author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name>
</author>
<author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A" last="Schwarzschild">Michael A. Schwarzschild</name>
</author>
<author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="doi">10.1002/mds.23191</idno>
<idno type="RBID">pubmed:20669249</idno>
<idno type="pmid">20669249</idno>
<idno type="wicri:Area/PubMed/Corpus">001701</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Calcium channel blocker use and risk of Parkinson's disease.</title>
<author><name sortKey="Simon, Kelly Claire" sort="Simon, Kelly Claire" uniqKey="Simon K" first="Kelly Claire" last="Simon">Kelly Claire Simon</name>
<affiliation><nlm:affiliation>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ksimon@hsph.harvard.edu</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name>
</author>
<author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name>
</author>
<author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A" last="Schwarzschild">Michael A. Schwarzschild</name>
</author>
<author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Calcium Channel Blockers (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Hypertension (drug therapy)</term>
<term>Male</term>
<term>Nurses</term>
<term>Parkinson Disease (etiology)</term>
<term>Proportional Hazards Models</term>
<term>Risk</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Calcium Channel Blockers</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Nurses</term>
<term>Proportional Hazards Models</term>
<term>Risk</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20669249</PMID>
<DateCreated><Year>2010</Year>
<Month>09</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>12</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>08</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>12</Issue>
<PubDate><Year>2010</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Calcium channel blocker use and risk of Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>1818-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23191</ELocationID>
<Abstract><AbstractText>We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.</AbstractText>
<CopyrightInformation>© 2010 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simon</LastName>
<ForeName>Kelly Claire</ForeName>
<Initials>KC</Initials>
<AffiliationInfo><Affiliation>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ksimon@hsph.harvard.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Honglei</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schwarzschild</LastName>
<ForeName>Michael A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ascherio</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 NS048517</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 NS048517</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 NS048517-05</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2001 Jul;50(1):56-63</RefSource>
<PMID Version="1">11456310</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2007 Jun 28;447(7148):1081-6</RefSource>
<PMID Version="1">17558391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1991 Feb 15;541(2):342-6</RefSource>
<PMID Version="1">1647250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 1997;50:79-88</RefSource>
<PMID Version="1">9120427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1997 Mar;68(3):1221-33</RefSource>
<PMID Version="1">9048769</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Feb 10;72(6):578-9</RefSource>
<PMID Version="1">19204275</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aging Cell. 2007 Jun;6(3):337-50</RefSource>
<PMID Version="1">17328689</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neural Transm. 2004 Aug;111(8):1031-40</RefSource>
<PMID Version="1">15254791</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2007 Oct;6(10):933-8</RefSource>
<PMID Version="1">17884683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 Apr 15;70(16 Pt 2):1438-44</RefSource>
<PMID Version="1">18256367</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2007 Apr;13(3):165-9</RefSource>
<PMID Version="1">17055323</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009726">Nurses</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS195921</OtherID>
<OtherID Source="NLM">PMC2939261</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.23191</ArticleId>
<ArticleId IdType="pubmed">20669249</ArticleId>
<ArticleId IdType="pmc">PMC2939261</ArticleId>
<ArticleId IdType="mid">NIHMS195921</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001701 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001701 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:20669249 |texte= Calcium channel blocker use and risk of Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20669249" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |